You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study

 

Online download statistics by month:

Online download statistics by month: December 2020 to May 2022

AbstractFullPdf
Dec 202016416446
Jan 2021273273136
Feb 202117217448
Mar 202120020147
Apr 202115315338
May 202115915935
Jun 202116916936
Jul 202113013023
Aug 202113113145
Sep 2021929247
Oct 202114214294
Nov 202110910749
Dec 2021989952
Jan 202212613851
Feb 2022878737
Mar 2022727272
Apr 2022788041
May 202211211249
Total24672483946